Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

First-year cost savings may be greater with etanercept in RA

    This is a preview of subscription content, log in to check access.

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    First-year cost savings may be greater with etanercept in RA. Pharmacoecon. Outcomes News 482, 10 (2005). https://doi.org/10.2165/00151234-200504820-00024

    Download citation

    Keywords

    • Rheumatoid Arthritis
    • Infliximab
    • Etanercept
    • Outcome News
    • Infliximab Therapy